Invivyd, Inc. SEC filings IVVD
Invivyd, Inc. has 448 filings in SEC EDGAR's recent list, going back to Nov 12, 2020. Its latest annual report, Form ARS, was filed on Apr 6, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 29, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 6, 2026 | — |
| DEF 14A | Proxy statement | Apr 6, 2026 | May 19, 2026 |
| DEFA14A | Additional proxy material | Apr 7, 2025 | — |
| DEF 14A | Proxy statement | Apr 7, 2025 | May 20, 2025 |
| DEF 14A | Proxy statement | Apr 18, 2024 | May 21, 2024 |
| DEFA14A | Additional proxy material | Apr 10, 2023 | — |
| DEF 14A | Proxy statement | Apr 10, 2023 | May 23, 2023 |
| PRE 14A | Preliminary proxy statement | Mar 31, 2023 | May 23, 2023 |
Showing 8 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IVVD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Haven, CT
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1832038
- Former names
- Adagio Therapeutics, Inc. (until Sep 12, 2022)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.